379,300 Shares in Bristol Myers Squibb Company $BMY Bought by Advisors Asset Management Inc.

Bristol Myers Squibb logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management bought 379,300 Bristol Myers Squibb shares in the third quarter, valued at approximately $23.7 million. Institutional investors collectively own 76.41% of the company’s stock.
  • Analyst opinions are mixed, with a consensus rating of Hold and an average price target of $65.46. Two analysts rate the stock Strong Buy, 11 Buy, 16 Hold, and one Sell.
  • Bristol Myers Squibb beat quarterly earnings and revenue estimates, reporting $1.35 per share and $13.07 billion in revenue; revenue rose 6.9% year over year. Its quarterly dividend of $0.63 per share equates to an annualized yield of about 4.3%.
  • Interested in Bristol Myers Squibb? Here are five stocks we like better.

Advisors Asset Management Inc. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 379,300 shares of the biopharmaceutical company's stock, valued at approximately $23,668,000.

Several other hedge funds and other institutional investors also recently modified their holdings of BMY. Edmond DE Rothschild Holding S.A. lifted its holdings in shares of Bristol Myers Squibb by 39.7% during the third quarter. Edmond DE Rothschild Holding S.A. now owns 158,621 shares of the biopharmaceutical company's stock worth $9,898,000 after purchasing an additional 45,084 shares during the period. Private Wealth Asset Management LLC increased its stake in Bristol Myers Squibb by 195.8% in the 3rd quarter. Private Wealth Asset Management LLC now owns 51,671 shares of the biopharmaceutical company's stock valued at $3,211,000 after buying an additional 34,201 shares during the period. Alteri Wealth LLC increased its stake in Bristol Myers Squibb by 8.4% in the 3rd quarter. Alteri Wealth LLC now owns 12,850 shares of the biopharmaceutical company's stock valued at $802,000 after buying an additional 995 shares during the period. USS Investment Management Ltd raised its position in Bristol Myers Squibb by 5.0% during the 3rd quarter. USS Investment Management Ltd now owns 412,085 shares of the biopharmaceutical company's stock worth $25,733,000 after buying an additional 19,800 shares during the last quarter. Finally, Berger Financial Group Inc raised its position in Bristol Myers Squibb by 10.0% during the 3rd quarter. Berger Financial Group Inc now owns 4,164 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 380 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Argus raised shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. Truist Financial set a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, October 30th. Leerink Partners downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $73.00 to $59.00 in a research report on Monday, October 5th. Wells Fargo & Company lowered their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating on the stock in a report on Tuesday, October 13th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of Bristol Myers Squibb in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus price target of $65.46.

Check Out Our Latest Report on BMY

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the transaction, the director directly owned 30,279 shares of the company's stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.05% of the company's stock.

Top Bristol Myers Squibb Stories

Here are a few of the latest stories about BMY:

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $58.81 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a fifty-two week low of $45.52 and a fifty-two week high of $68.64. The stock has a market cap of $120.22 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. The firm's fifty day simple moving average is $61.45 and its 200-day simple moving average is $60.44.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm had revenue of $13.07 billion during the quarter, compared to analysts' expectations of $12.72 billion. During the same quarter last year, the business earned $1.63 earnings per share. The business's revenue for the quarter was up 6.9% compared to the same quarter last year. Analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb's payout ratio is 55.88%.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bristol Myers Squibb Right Now?

Before you consider Bristol Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.

While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines